InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases
JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...